4[5]Moses R,Slobodniuk R,Boyages S,et al.Additional treatment with repaglinide provides significant improvement in glycemic controling NIDDM patients poorly controlled on metformin[C].57th Scientific Sessions of the American Dabetes Association,Boston,MA,USA,1997.
5[6]Moses r,Slobodniuk R,Boyages S,et al.Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes[J].DiabetesCare,1999,22:1192124.
1Owens DR,Cozma LS,Luzio SD. Early-phase prandial insulin secretion:its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide[J]. Diabetes Nutr Metab,2002,15(6 suppl):19-27
2Hasslacher C, Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function[J].Diabetes Care,2003,26(3):886-891
3Moses R. Repaglinide in combination therapy[J].Diabetes Nutr Metab,2002 15(6 suppl):33-38
4Widom B, Weakland BS. Mechanisms of weight gain during intensive insulin therapy (Abstract).Diabetes,1992, 41(suppl) :31.
5Taskinan MR, sane T, Helve E, et al. Bestime insulin for suppression of overnight free fatty acid, blood glucose and glucose producion in NIDDM. Diabetes, 1989, 38: 588.
6Teonier B, Marbury TC, Dansbo P, et al. Aneworal hypoglycamicagent, repaglinide, minimizesrisk of hypoglycaemiainwell-controlled NIDDM patients[J]. Diabetologia, 1995,38 : 752.
7Wolffenbattel BHR, Landgraf R. A 1-year multicenterr and omized double-blind comparisonofre paglinide and glyburide for treatment of type 2 diabetes[J]. Diabetes Care, 1999,22:463 - 467.
8段文澜,刘红编译.1996年欧洲糖尿病专题会议纪要[C].糖尿病论坛,1997,1:6.
9Anonymous,Repaglinide:A challenge to the sulphonylureas[J].Drugs and Therapy Perspectives 1998;12:1-5.
10Hatorp V,Hasslacher C.Clauson P.Pharmacokinetics of repaglinide in type 2 diabetes patients with and without renal impairment[J].Diabetologia 1999,42(Suppl 1):112.
3American Diabetes Association.Standards of medical care in diabetes-2006[J].Diabetes Care,2006,29(Suppl 1):S4-S42.
4Davis TM,Colagiuri S.The continuing legacy of the united kingdom prospective diabetes study[J].Med J Aust,2004,180(3):104-105.
5American Diabetes Association.Standards of medical care in diabetes[J].Diabetes Care,2004,27(Suppl 1):S15-S35.
6WHO: The World Health Report. World Health Organization, Geneva, 1998.
7Yang WY, l_,u JM, Weng JP, et al. Prevalence of Diabetes among Men and Women in China [J]. N Engl J Med, 2010, 362 (12): 1090-1101.
8American Diabetes Association. Standards of medical care in dia- betes-2006 [J]. Diabetes care, 2006,29 (Suppll): $4-$42.
9Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypogly- cemia [J]. Diabetes Care, 2005, 28 (5): 1245-1249.
10Davis TM, Colagiuri S. The continuing legacy of the United Kingdom Prospective Diabetes Study [J]. Med J Aust, 2004, 180 (3): 104-105.
